迪哲医药2025年净亏损7.63亿元

Core Viewpoint - The company reported significant revenue growth for 2025, with total revenue reaching 801 million yuan, a year-on-year increase of 122.6%, while the net loss decreased to 763 million yuan from 846 million yuan in the previous year [1] Financial Performance - Total revenue for 2025 was 801 million yuan, reflecting a 122.6% increase compared to the previous year [1] - The net loss attributable to the parent company was 763 million yuan, an improvement from a loss of 846 million yuan in the prior year [1] Product Development and Market Impact - Two products,舒沃哲® (generic name:舒沃替尼片) and高瑞哲® (generic name:戈利昔替尼胶囊), were included in the national medical insurance drug list for the first time, enhancing patient accessibility [1] - The company has intensified product promotion efforts and is actively expanding market share, positively impacting its operations [1]